Coherus BioSciences’ (CHRS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $7.00 price target on the biotechnology company’s stock.

Several other equities research analysts have also recently commented on the company. UBS Group reissued a “neutral” rating and issued a $1.05 price target (down previously from $1.50) on shares of Coherus BioSciences in a research note on Thursday, April 24th. StockNews.com downgraded Coherus BioSciences from a “hold” rating to a “sell” rating in a research note on Tuesday, April 15th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $5.26.

Coherus BioSciences Stock Performance

Shares of CHRS opened at $1.05 on Tuesday. The company has a market capitalization of $121.69 million, a PE ratio of -13.13 and a beta of 1.01. The company’s 50 day moving average price is $0.96 and its 200 day moving average price is $1.12. Coherus BioSciences has a 52 week low of $0.66 and a 52 week high of $2.43.

Institutional Investors Weigh In On Coherus BioSciences

Several institutional investors have recently added to or reduced their stakes in CHRS. Charles Schwab Investment Management Inc. grew its stake in Coherus BioSciences by 1.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 976,857 shares of the biotechnology company’s stock valued at $1,348,000 after purchasing an additional 12,530 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Coherus BioSciences by 32.4% in the 4th quarter. Wells Fargo & Company MN now owns 61,830 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 15,137 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in Coherus BioSciences by 97.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 30,847 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 15,214 shares during the period. CWM LLC lifted its position in shares of Coherus BioSciences by 96.6% in the first quarter. CWM LLC now owns 49,793 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 24,468 shares during the last quarter. Finally, Bank of Montreal Can bought a new position in shares of Coherus BioSciences during the 4th quarter worth approximately $34,000. 72.82% of the stock is owned by institutional investors.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.